What is the max dose of mepivacaine?

The maximum dose of mepivacaine without epinephrine is 5 mg/kg, with an absolute maximum of 400 mg. With epinephrine, the maximum dose increases to 6.6-7 mg/kg, with an absolute maximum of 500 mg. Pediatric patients (children and adolescents) follow similar weight-based limits of 5-7 mg/kg without epinephrine and 7 mg/kg with epinephrine, but neonates and infants require significant dose reductions.

What is the mepivacaine dose with epinephrine?

With epinephrine, the maximum recommended dose of mepivacaine for adults is 6.6-7 mg/kg, up to an absolute maximum of 500 mg. Epinephrine causes local vasoconstriction, slowing systemic absorption and effectively increasing the safe dose ceiling. For pediatric patients, the maximum with epinephrine is 7 mg/kg, though neonates (50% of standard), young infants (70%), and older infants (75%) require tier-based reductions.

Is mepivacaine safe for pediatric patients?

Mepivacaine can be used in pediatric patients with appropriate dose adjustments. Children (1-7 years) and adolescents (8+ years) use the full weight-based dose of 5-7 mg/kg without epinephrine and 7 mg/kg with epinephrine. However, younger patients require significant reductions: neonates (<1 month) receive only 50% of the standard dose, young infants (1-6 months) receive 70%, and older infants (6-12 months) receive 75%. These reductions reflect immature hepatic metabolism and higher sensitivity to local anesthetic toxicity.

Mepivacaine Dosing

Maximum Dose Reference for Adults & Pediatrics

Intermediate-duration amide local anesthetic — commonly used in dental and regional anesthesia

CLINICAL REFERENCE ONLY. This page is a decision support tool for licensed healthcare professionals. It does not replace clinical judgment. Always verify doses against current guidelines, institutional protocols, and patient-specific factors before administration.

Adult Dosing

Without Epinephrine

Parameter	Value
Maximum dose (mg/kg)	5 mg/kg
Absolute maximum (mg)	400 mg

With Epinephrine

Parameter	Value
Maximum dose (mg/kg)	6.6–7 mg/kg
Absolute maximum (mg)	500 mg

Weight basis: For adults with BMI < 30, use total body weight. For adults with BMI ≥ 30, use lean body weight (Janmahasatian 2005 equation). The conservative lower bound (5 mg/kg without epi, 6.6 mg/kg with epi) is used as the fractional toxicity denominator.

Pediatric Dosing

Base Dose (Child & Adolescent)

Parameter	Without Epinephrine	With Epinephrine
Maximum dose (mg/kg)	5–7 mg/kg	7 mg/kg

Note: Pediatric mepivacaine dose limits (5–7 mg/kg without epi) differ from the adult value (5 mg/kg without epi). Children and adolescents may use the higher range based on clinical context. Always use the conservative lower bound for fractional toxicity calculations.

Age-Tier Dose Reductions

Standard pediatric tier reductions apply to the base dose:

Age Tier	Age Range	Dose Factor	Effective Max (no epi)	Effective Max (with epi)
Neonate	< 1 month	50%	2.5–3.5 mg/kg	3.5 mg/kg
Young Infant	1 – < 6 months	70%	3.5–4.9 mg/kg	4.9 mg/kg
Older Infant	6 – < 12 months	75%	3.75–5.25 mg/kg	5.25 mg/kg
Child	1 – 7 years	100%	5–7 mg/kg	7 mg/kg
Adolescent	8+ years	100%	5–7 mg/kg	7 mg/kg

NEONATAL CAUTION. Neonates (<1 month) have immature hepatic enzyme systems and reduced protein binding, resulting in higher free drug levels. The 50% dose reduction is mandatory. Monitor closely for signs of systemic toxicity — neonates may present with sudden cardiovascular collapse without prodromal CNS symptoms.

Pharmacokinetics

Parameter	Value
Classification	Amide local anesthetic (intermediate duration)
Onset	3–5 minutes (infiltration); 15–20 minutes (peripheral nerve block)
Duration without epinephrine	45–90 minutes
Duration with epinephrine	120–360 minutes (block-dependent)
pKa	7.6
Protein binding	~78%
Metabolism	Hepatic (CYP enzymes — amide hydrolysis)
Elimination half-life	1.9–3.2 hours (adult)
Available concentrations	1%, 1.5%, 2%, 3% (dental cartridges)

Clinical Notes

Intermediate duration: Mepivacaine provides intermediate-duration anesthesia, longer than lidocaine but shorter than bupivacaine. This makes it well suited for procedures lasting 1–3 hours.
Dental use: Mepivacaine is one of the most commonly used local anesthetics in dentistry. The 3% plain (without epinephrine) formulation is particularly popular for short dental procedures where vasoconstriction is not desired.
Lower pKa advantage: With a pKa of 7.6 (closer to physiologic pH than most amides), mepivacaine has a faster onset than bupivacaine (pKa 8.1) and a higher proportion of un-ionized drug at tissue pH.
No vasoconstriction needed: Mepivacaine produces mild inherent vasoconstriction at clinical concentrations, unlike lidocaine which is vasodilatory. This is why the plain (no-epinephrine) formulation remains effective.
Hepatic metabolism: As an amide local anesthetic, mepivacaine is metabolized by the liver. Reduce doses in patients with significant hepatic impairment, congestive heart failure, or reduced hepatic blood flow.
Fractional toxicity: When mepivacaine is administered with other local anesthetics, total systemic toxicity is additive. Use fractional toxicity calculations to track cumulative dose burden across all agents.

Epinephrine considerations: Epinephrine increases the safe dose ceiling by slowing systemic absorption. However, avoid epinephrine-containing solutions for digital blocks, penile blocks, and in patients where vasoconstriction is contraindicated.

Calculate Mepivacaine Doses with MaxLocal

Weight-based dosing, pediatric age-tier reductions, fractional toxicity tracking, and instant LAST protocol access — all offline, on your phone.

Get MaxLocal on Google Play

Learn more at max-local.app

Related Dosing Guides

References

Rosenberg PH, Veering BT, Urmey WF. Maximum recommended doses of local anesthetics: a multifactorial concept. Reg Anesth Pain Med. 2004;29(6):564-575.
Neal JM, Barrington MJ, Fettiplace MR, et al. The Third ASRA Practice Advisory on Local Anesthetic Systemic Toxicity. Reg Anesth Pain Med. 2020;45(4):247-253.
Becker DE, Reed KL. Local anesthetics: review of pharmacological considerations. Anesth Prog. 2012;59(2):90-102.
Heavner JE. Local anesthetics. Curr Opin Anaesthesiol. 2007;20(4):336-342.
Butterworth JF, Strichartz GR. Molecular mechanisms of local anesthesia: a review. Anesthesiology. 1990;72(4):711-734.

Clinical Decision Support Tool. This page is intended as a reference aid for licensed healthcare professionals only. It does not replace clinical judgment. Always verify information against current guidelines and institutional protocols. Not for patient self-medication.